Literature DB >> 24578142

Incident heart failure in relation to vascular disease: insights from the Health, Aging, and Body Composition Study.

Hassan Khan1, Andreas P Kalogeropoulos, Faiez Zannad, Catherine N Marti, Peter W F Wilson, Vasiliki V Georgiopoulou, Alka M Kanaya, Anne B Newman, Erik Schelbert, Tamara B Harris, Stephen Kritchevsky, Clyde Yancy, Mihai Gheorghiade, Gregg C Fonarow, Javed Butler.   

Abstract

AIMS: The contribution of heart failure (HF) unrelated to vascular disease to the overall HF burden in older adults is not well characterized. This was investigated in this study. METHODS AND
RESULTS: We assessed HF incidence and outcomes in 2895 participants of the Health ABC Study (age 74 ± 3 years, 48.4% men, 41.4% black) in relation to vascular disease (coronary, peripheral, or cerebrovascular disease) either present at baseline or developed prior to HF. During 11.4 years follow-up, 493 participants developed HF; 134 (27.2%) in participants without any prior vascular disease and 177 (36.8%) without coronary disease. Both baseline [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.9-2.8] and incident vascular disease (HR 4.3, 95% CI 3.6-5.2) were associated with HF. During a median follow-up of 2.1 years after HF onset, 67.5% participants died. Annual mortality after HF development was 21.3% in those with compared with 24.6% in those without vascular disease (HR 1.11, 95% CI 0.87-1.43; P = 0.399). There were 658 all-cause (436.3/1000 person-years) and 523 HF-related (346.4/1000 person-years) hospitalizations after HF development. There was no significant difference in hospitalizations between those with and without vascular disease [rate ratio (RR) 1.04, 95% CI 0.86-1.24 for all-cause, and RR 0.84 95% CI 0.69-1.02 for HF hospitalization]. HF with preserved EF was more common in participants without vascular disease (67.0% vs. 55.0%, P = 0.040).
CONCLUSION: A significant proportion of HF in older adults develops without prior vascular disease. Outcomes for these patients are poor compared with those with preceding vascular disease. These data suggest the need for more targeted HF prediction and prevention efforts.
© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.

Entities:  

Keywords:  Epidemiology; Heart failure; Race; Sex

Mesh:

Year:  2014        PMID: 24578142      PMCID: PMC4648241          DOI: 10.1002/ejhf.69

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  47 in total

Review 1.  Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part II: the aging heart in health: links to heart disease.

Authors:  Edward G Lakatta; Daniel Levy
Journal:  Circulation       Date:  2003-01-21       Impact factor: 29.690

Review 2.  From risk factors to structural heart disease: the role of inflammation.

Authors:  Andreas P Kalogeropoulos; Vasiliki V Georgiopoulou; Javed Butler
Journal:  Heart Fail Clin       Date:  2011-10-13       Impact factor: 3.179

Review 3.  Inflammatory markers in population studies of aging.

Authors:  Tushar Singh; Anne B Newman
Journal:  Ageing Res Rev       Date:  2010-12-08       Impact factor: 10.895

4.  Incident heart failure prediction in the elderly: the health ABC heart failure score.

Authors:  Javed Butler; Andreas Kalogeropoulos; Vasiliki Georgiopoulou; Rhonda Belue; Nicolas Rodondi; Melissa Garcia; Douglas C Bauer; Suzanne Satterfield; Andrew L Smith; Viola Vaccarino; Anne B Newman; Tamara B Harris; Peter W F Wilson; Stephen B Kritchevsky
Journal:  Circ Heart Fail       Date:  2008-07       Impact factor: 8.790

5.  Reduced vascular tetrahydrobiopterin (BH4) and endothelial function with ageing: is it time for a chronic BH4 supplementation trial in middle-aged and older adults?

Authors:  Gary L Pierce; Thomas J Larocca
Journal:  J Physiol       Date:  2008-04-03       Impact factor: 5.182

Review 6.  The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening.

Authors:  Thomas J Wang; Daniel Levy; Emelia J Benjamin; Ramachandran S Vasan
Journal:  Ann Intern Med       Date:  2003-06-03       Impact factor: 25.391

7.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

8.  Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study).

Authors:  Matteo Cesari; Brenda W J H Penninx; Anne B Newman; Stephen B Kritchevsky; Barbara J Nicklas; Kim Sutton-Tyrrell; Russell P Tracy; Susan M Rubin; Tamara B Harris; Marco Pahor
Journal:  Am J Cardiol       Date:  2003-09-01       Impact factor: 2.778

9.  The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study.

Authors:  Irene Betti; Gabriele Castelli; Alessandro Barchielli; Cinzia Beligni; Vittorio Boscherini; Leonardo De Luca; Gianni Messeri; Mihai Gheorghiade; Alan Maisel; Alfredo Zuppiroli
Journal:  J Card Fail       Date:  2009-01-21       Impact factor: 5.712

10.  Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults.

Authors:  Erik B Schelbert; Jie J Cao; Sigurdur Sigurdsson; Thor Aspelund; Peter Kellman; Anthony H Aletras; Christopher K Dyke; Gudmundur Thorgeirsson; Gudny Eiriksdottir; Lenore J Launer; Vilmundur Gudnason; Tamara B Harris; Andrew E Arai
Journal:  JAMA       Date:  2012-09-05       Impact factor: 56.272

View more
  3 in total

1.  Arterial Stiffness and Risk of Overall Heart Failure, Heart Failure With Preserved Ejection Fraction, and Heart Failure With Reduced Ejection Fraction: The Health ABC Study (Health, Aging, and Body Composition).

Authors:  Ambarish Pandey; Hassan Khan; Anne B Newman; Edward G Lakatta; Daniel E Forman; Javed Butler; Jarett D Berry
Journal:  Hypertension       Date:  2016-12-19       Impact factor: 10.190

2.  Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.

Authors:  David Fitchett; Silvio E Inzucchi; Christopher P Cannon; Darren K McGuire; Benjamin M Scirica; Odd Erik Johansen; Steven Sambevski; Stefan Kaspers; Egon Pfarr; Jyothis T George; Bernard Zinman
Journal:  Circulation       Date:  2019-03-12       Impact factor: 29.690

3.  Clinical evidence and treatment requirements related to heart failure in type 2 diabetes mellitus.

Authors:  Xiao-Ling Cai; Xiang-Qing Wang; Li-Nong Ji
Journal:  Chin Med J (Engl)       Date:  2020-05-20       Impact factor: 2.628

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.